The observation that these cells were more sensitive to p110α inhibition than WT PIK3CA is in agreement with the studies of Torbett et al [12] showing that breast cancer cells with PIK3CA mutations in their catalytic domain responded to the p110α inhibitor PIK-75, but not PTEN-deficient cells. This evidence concerns the gene PTEN and breast carcinoma.